BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36225930)

  • 1. CAR-T manufactured from frozen PBMC yield efficient function with prolonged
    Abraham-Miranda J; Menges M; Atkins R; Mattie M; Kanska J; Turner J; Hidalgo-Vargas MJ; Locke FL
    Front Immunol; 2022; 13():1007042. PubMed ID: 36225930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cryopreservation on CAR T production and clinical response.
    Brezinger-Dayan K; Itzhaki O; Melnichenko J; Kubi A; Zeltzer LA; Jacoby E; Avigdor A; Shapira Frommer R; Besser MJ
    Front Oncol; 2022; 12():1024362. PubMed ID: 36276077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T.
    Ruggeri Barbaro N; Drashansky T; Tess K; Djedaini M; Hariri R; He S; van der Touw W; Karasiewicz K
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38684370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
    Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
    Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.
    Elavia N; Panch SR; McManus A; Bikkani T; Szymanski J; Highfill SL; Jin P; Brudno J; Kochenderfer J; Stroncek DF
    Transfusion; 2019 May; 59(5):1755-1764. PubMed ID: 30973976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplified process for the production of anti-CD19-CAR-engineered T cells.
    Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
    Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.
    Su T; Ying Z; Lu XA; He T; Song Y; Wang X; Ping L; Xie Y; Tu M; Liu G; Qi F; Ding Y; Jing H; Zhu J
    Cryobiology; 2020 Oct; 96():106-113. PubMed ID: 32721392
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
    Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
    Front Immunol; 2022; 13():836549. PubMed ID: 35222427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
    de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.
    Stroncek DF; Lee DW; Ren J; Sabatino M; Highfill S; Khuu H; Shah NN; Kaplan RN; Fry TJ; Mackall CL
    J Transl Med; 2017 Mar; 15(1):59. PubMed ID: 28298232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells.
    Sayadmanesh A; Azadbakht M; Yari K; Abedelahi A; Shafaei H; Shanehbandi D; Baradaran B; Basiri M
    Cell J; 2023 Oct; 25(10):674-687. PubMed ID: 37865876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.